AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03155893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMV Placebo (Matching 150 mg SMV)
Description: Participants will receive SMV Placebo (matching 150 mg SMV \[2\*75 mg capsules\]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.
Study NCT03155893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335 Placebo (matching 1200 mg AL-335)
Description: Participants will receive a single dose of AL-335 placebo (matching 1200 mg AL-335 \[3\*400 mg tablets\]) administered orally on Day 15 in Treatment A and B.
Study NCT03155893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo (matching 400 mg moxifloxacin)
Description: Participants will receive a single dose of moxifloxacin placebo (matching 400 mg moxifloxacin \[1\*400 mg capsule\]) administered orally on Day 1, 15 and 16 in Treatment A, on Day 1, 2 and 15 in Treatment B and on Day 1, 2, 15 and 16 in Treatment C.
Study NCT03155893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV 25 mg
Description: Participants will receive ODV 25 mg orally once daily administered on Days 2 to 16 in Treatment C.
Study NCT03155893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV 200 mg
Description: Participants will receive ODV 200 mg (4\*50 mg tablets) orally once daily will be administered on Days 1 and 2 in Treatment F.
Study NCT03155893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV 125 mg
Description: Participants will receive ODV 125 mg (2\*50 mg tablets + 1\*25 mg tablets) once daily administered on Days 3 to 7 in Treatment F.
Study NCT03155893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV 100 mg
Description: Participants will receive ODV 100 mg (2\*50 mg tablets) orally once daily administered on Days 8 to 14 in Treatment F.
Study NCT01384071 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intervention (Adidas shoes)
Description: Normal stable shoes (Adidas Bigroar2)
Study NCT04406285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol Leukemia
Description: * Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets).
Study NCT04406285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodic Resistance Training Program Leukemia
Description: * Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels.
Study NCT03155893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMV 150 mg
Description: Participants will receive SMV 150 mg (2\*75 mg capsules) orally once daily administered on Days 2 to 16 in Treatment C.
Study NCT03155893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335 1200 mg
Description: Participants will receive a single oral dose of AL-335 1200 mg (3\*400 mg tablets) administered on Day 15 in Treatment C.
Study NCT04315779 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salpingectomy
Description: Patients will undergo removal of the affected tube
Study NCT01239498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of Saline + Lidocaine/Adrenaline
Description: All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The experimental eyelid will receive a saline-consisted injection 0.5cc prior to the administration of the anesthetic injection.~Injection of Saline + Lidocaine 1%
Study NCT04406285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol Lymphoma
Description: * Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets).
Study NCT04406285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodic Resistance Training Program Lymphoma
Description: * Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels.
Study NCT04349085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effective PBMT/sMF
Description: A cluster with 20 diodes, manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used: 4 diodes of 905 nm (1.25 average power, 50 W of peak power for each diode), 8 diodes of 850 nm (40 mW of average power for each diode) and 4 diodes of 633 nm (25 mW average power for each diode). Effective PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The effective PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 270 J for knee extensors/hip flexors, 180 J for knee flexors/hip extensors, and 60 J for plantar flexors.
Study NCT04349085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo PBMT/sMF
Description: A cluster manufactured by Multi Radiance Medical® (Solon, OH, USA) with 20 diodes will be used: Placebo PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The placebo PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
Study NCT04349085 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT/sMF
Description: A cluster manufactured by Multi Radiance Medical® (Solon, OH, USA) with 20 diodes will be used: Placebo PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The placebo PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
Study NCT01143207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Description: Injectable hormonal contraceptive
Study NCT03611010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin injection
Description: statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection
Study NCT00788398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: Irrigation with Saline
Study NCT00788398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soap solution
Description: Irrigation with Castile Soap Solution (80 ml per 3L bag of saline)
Study NCT00788398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gravity Flow Irrigation
Description: Gravity flow irrigation will be standardized across participating centers as 3L bags of normal saline (alone or with soap solution) suspended 6-8 feet above floor level using an I.V. pole. Irrigation tubing (measuring 1/4 - 3/8 inch inner diameter) will be connected to the 3L bag and secured with a stopcock (or compressive device) until ready for use.
Study NCT00788398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Pressure Irrigation
Description: Irrigation with the Stryker SurgiLav System. At the low pressure setting delivers 5.9 p.s.i. pressure. The high-flow irrigator tip will be held perpendicular to and 5cm above the wound.~Irrigation with the Zimmer PulsaVac. For low pressure delivery, the shower tip will be used at the low pressure setting which delivers a pressure of 5.8 p.s.i.
Study NCT00788398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Pressure
Description: Irrigation with the Stryker SurgiLav System. For the high pressure delivery, the multi-orifice tip will be used at the high setting which delivers a pressure of 30 p.s.i.~Irrigation with the Zimmer PulsaVac System: For the high pressure delivery the shower tip will be used at the high pressure setting which delivers a pressure of 23 p.s.i.
Study NCT02063880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urgent ART
Description: Children will be started on HAART \<48 hours after enrollment.
Study NCT02063880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early ART
Description: Children will be started on ART after stabilization 7-14 days after enrollment.
Study NCT01239498 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine/Adrenaline only
Description: Injection of Lidocaine/Adrenaline only
Study NCT02806063 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: intraoperative samples
Study NCT02835755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive standard HPV and HPV vaccine information
Study NCT02835755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive mHealth HPV vaccine intervention
Study NCT02835755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02835755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03359941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture points: Examples of acupuncture points to be used include BL23 (Sinsu, bilateral), BL24(Gihaesu, bilateral), BL25(Daejangsu, bilateral), BL40(Wijung, bilateral), BL60(Gollyun, bilateral), BL65(Sokgol, bilateral), LI11(Gokji, bilateral), LI4(Hapgok, bilateral), ST36(Joksamni, bilateral), GB41(Jogimeup, bilateral), LR3(Taechung, bilateral). Electrical stimulation with alternating frequency of 2-100 Hz will be applied to the selected points (e.g., BL 23-25, bilateral). Treatments will be provided by qualified Korean traditional medicine doctors with more than 2 years of clinical experience.
Study NCT02441322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novo-TTF
Description: Procedures: MRI and advanced MRI sequence Advanced brain MRI's with special sequences will be obtained. First MRI prior to starting Novo-TTF therapy, second MRI up to 2-3 weeks after beginning therapy, third MRI up to 2 months from starting treatment and the last MRI up to 4 months after starting treatment.
Study NCT02834390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: \[Induction period, Cycle 1\] Once-daily repeated oral administration Day 8 to Day 21.~\[Induction period, Cycle 2\] Once-daily repeated oral administration Day 6 to Day 19.~\[Consolidation period\] Once-daily repeated oral administration Day 6 to Day 19.
Study NCT02834390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: \[Induction period, Cycle 1\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 7.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 5.~\[Consolidation period\] Twice-daily intravenous injection of 3.0 g/m\^2 cytarabine at 12-hour intervals on Days 1, 3, and 5.
Study NCT02834390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 and 2.
Study NCT02834390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 and 2.
Study NCT00939523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: All participants will be asked to take Lapatinib daily for six months during the research study.
Study NCT02327325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
Study NCT02327325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Telephone-based training in multiple skills for managing low back pain.
Study NCT02966730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered orally, on a once daily continuous dosing schedule and in an outpatient setting. Treatment will continue for 2 years and there will be no planned treatment breaks. The dose of Ibrutinib will be initiated at 560mg per day, which will remain constant throughout the study period, unless otherwise specified.
Study NCT00658034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Subjects will receive acupuncture weekly for six weeks. Subjects will complete a Brief Fatigue Inventory (BFI) questionnaire, a Functional Assessment of Cancer Treatment scale (FACT-G), and a Hospital Anxiety and Depression Scale(HADS) at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why.
Study NCT00658034 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo Acupuncture
Description: Subjects will receive placebo acupuncture weekly for six weeks. During the placebo phase, placebo acupuncture needles will be applied a few mm away from the required points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. When it is pressed against the skin, the subject feels a slight prick and sees the handle of the needle moving towards the skin as if the needle has been inserted.~Subjects will complete a BFI, a FACT-G, and a HADS at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why. Subjects in the placebo group will be given the option to receive true acupuncture.
Study NCT04011098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural Fentanyl Bolus
Description: Fentanyl bolus refers to the provision of a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia (0.08% Bupivicaine with 2 mcg/ml Fentanyl Solution).
Study NCT04011098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Epidural Group
Description: The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care infusion of the same solution, with a PCEA pump for subsequent analgesia.
Study NCT03426540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: Three-port 25-G PPV was performed in all patients using a Constellation system. Patients in the treatment group received an intravitreal injection of conbercept (10 mg/mL, 0.5 mg) using a sterile technique after 25-G vitrectomy.
Study NCT03310593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol as active intervention.
Study NCT03310593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention.
Study NCT00907205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF1126
Description: Dose Escalating with 3+ patients in each cohort
Study NCT02421627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moxibustion
Description: Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral). using mild-warm moxibustion，the surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
Study NCT02421627 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham moxibustion
Description: Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral); using sham mild-warm moxibustion，the surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
Study NCT02941523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 administration
Study NCT02941523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administration
Study NCT04449341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Go headset with Ocean Rift application
Description: Information already included in arm description
Study NCT00027417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liothyronine sodium/triiodothyronine
Study NCT00027417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liothyronine sodium/triiodothyronine
Study NCT00027417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary bypass and cardiac surgery
Study NCT00027417 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiopulmonary bypass and cardiac surgery
Study NCT02266940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a suspension
Description: DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
Study NCT02266940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a tablet
Description: A 200 mg DS 1971a tablet for oral administration
Study NCT02413034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Cefazolin (vancomycin in the case of allergy to cefazolin)
Study NCT02413034 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: no antibiotic prophylaxis
Study NCT03467737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal sorghum porridge, algal starch
Description: Normal sorghum porridge with 13C-labeled algal starch was fed, breath tested, as the first arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
Study NCT03467737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal sorghum porridge, algal dextrins
Description: Normal sorghum porridge with 13C-labeled starch limit dextrins was fed, breath tested, as the second arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
Study NCT03467737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal sorghum porridge, labeled flour
Description: Normal sorghum porridge with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
Study NCT03467737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified sorghum porridge, labeled flour
Description: Modified sorghum porridge with shear stirring to reduce viscosity with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
Study NCT03467737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thinned sorghum porridge, labeled flour
Description: Thinned sorghum porridge treated with an alpha-amylase liquifying enzyme with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
Study NCT03467737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified sorghum porridge, octanoic acid
Description: Modified sorghum porridge with shear stirring to reduce viscosity with addition of 13C-labeled octanoic acid was fed, breath tested, for gastric emptying assessment in healthy and moderately malnourished children.
Study NCT00696683 — intervention group
Intervention type: OTHER
Intervention: None, this is an observational study
Study NCT02647840 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: voice therapy
Description: voice therapy based on Estill Voice Model The study will provide primarily direct intervention, i.e. working directly on the voice with voice exercises based on the Estill model of voice. This will be structured and hierarchical. Participants will work through the content one-to-one with the voice specialist SLT at their level and pace, to suit their specific vocal needs, again reflecting current clinical practice. Participants may need fewer or more than four sessions to gain the required skills. Should patients need more than six session of voice therapy to recover their voice fully, final assessment for the study purposes will be taken at session 6, and voice therapy will continue as required.